KR960034164A - 스틸벤 유도체 및 이를 함유하는 약제학적 조성물 - Google Patents

스틸벤 유도체 및 이를 함유하는 약제학적 조성물 Download PDF

Info

Publication number
KR960034164A
KR960034164A KR1019960005884A KR19960005884A KR960034164A KR 960034164 A KR960034164 A KR 960034164A KR 1019960005884 A KR1019960005884 A KR 1019960005884A KR 19960005884 A KR19960005884 A KR 19960005884A KR 960034164 A KR960034164 A KR 960034164A
Authority
KR
South Korea
Prior art keywords
stilbene derivative
salt
pharmaceutical compositions
compositions containing
amino acid
Prior art date
Application number
KR1019960005884A
Other languages
English (en)
Other versions
KR100352048B1 (ko
Inventor
도시히로 하타나카
고지 오스미
다카시 쓰지
유키오 니헤이
류스케 나카가와
가즈오 오이시
Original Assignee
이나모리 쥰스케
아지노모토 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이나모리 쥰스케, 아지노모토 가부시키가이샤 filed Critical 이나모리 쥰스케
Publication of KR960034164A publication Critical patent/KR960034164A/ko
Application granted granted Critical
Publication of KR100352048B1 publication Critical patent/KR100352048B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/33—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated

Abstract

본 발명은 제암제로서 효과적으로 독성이 낮은 일반식(Ⅰ)의 스틸벤 유도체 또는 약제학적으로 허용되는 이의 염에 관한 것이다.
상기 식에서, X는 수소원자 또는 니트릴 그룹이고, Y는 아미노산 아실 그룹이다.

Description

스틸벤 유도체 및 이를 함유하는 약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 일반식(Ⅰ)의 스틸벤 유도체 또는 약제학적으로 허용되는 이의 염.
    상기 식에서, X는 수소원자 또는 니트릴 그룹이고, Y는 아미노산 아실 그룹이다.
  2. 제1항에 있어서, X가 수소원자인 스틸벤 유도체 또는 이의 염.
  3. 제1항에 있어서, X가 니트릴 그룹인 스틸벤 유도체 또는 이의 염.
  4. 제1항 또는 제2항에 있어서, Y가 L-α-아미노산 아실린 스틸벤 유도체 또는 이의 염.
  5. 제4항에 있어서, Y가 트레오닌인 스틸벤 유도체 또는 이의 염.
  6. 제4항에 있어서, Y가 세린인 스틸벤 유도체 또는 이의 염.
  7. 약제학적 용도를 위한, 제1항 내지 제6항 중의 어느 한 항에 따르는 화합물.
  8. 제1항 내지 제6항 중의 어느 한 항에 따르는 화합물과 약제학적으로 허용되는 부형제, 희석제 또는 담체를 포함하는 제암성 조성물.
  9. 제암제를 제조하기 위한, 제1항 내지 제6항 중의 어느 한 항에 따르는 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960005884A 1995-03-07 1996-03-07 스틸벤유도체및이를함유하는약제학적조성물 KR100352048B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP95-047581 1995-03-07
JP4758195 1995-03-07

Publications (2)

Publication Number Publication Date
KR960034164A true KR960034164A (ko) 1996-10-22
KR100352048B1 KR100352048B1 (ko) 2003-05-12

Family

ID=12779227

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960005884A KR100352048B1 (ko) 1995-03-07 1996-03-07 스틸벤유도체및이를함유하는약제학적조성물

Country Status (12)

Country Link
US (1) US5674906A (ko)
EP (1) EP0731085B1 (ko)
KR (1) KR100352048B1 (ko)
CN (1) CN1066713C (ko)
AT (1) ATE185792T1 (ko)
CA (1) CA2171275C (ko)
DE (1) DE69604714T2 (ko)
DK (1) DK0731085T3 (ko)
ES (1) ES2137628T3 (ko)
GR (1) GR3032311T3 (ko)
PT (1) PT731085E (ko)
TW (1) TW334418B (ko)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4470321B2 (ja) * 1998-04-03 2010-06-02 味の素株式会社 抗腫瘍剤
US6245814B1 (en) 1998-05-08 2001-06-12 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6624197B1 (en) 1998-05-08 2003-09-23 Calyx Therapeutics, Inc. Diphenylethylene compounds
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
US20020002200A1 (en) * 2000-02-04 2002-01-03 Bishwagit Nag Novel diphenylethylene compounds
US6525093B1 (en) 1999-11-08 2003-02-25 Calyx Therapeutics Inc. Compounds to treat diabetes and associated conditions
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
DE60129536T2 (de) 2000-03-10 2008-06-19 Baylor University, Waco Tubulin bindende liganden
PT1264821E (pt) * 2000-03-17 2008-08-12 Ajinomoto Kk Novos cristais de derivado de estilbeno e processo para a sua produção
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US20050153939A1 (en) * 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
YU29803A (sh) 2000-10-27 2006-05-25 Aventis Pharma S.A. Kombinacija kamptotekina i derivata stilbena za lečenje raka
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
DK1407784T3 (da) * 2001-06-25 2011-02-28 Ajinomoto Kk Antitumormidler
JPWO2003041740A1 (ja) * 2001-11-16 2005-03-03 味の素株式会社 腫瘍壊死剤
FR2838437B1 (fr) * 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
US6759555B2 (en) * 2002-04-11 2004-07-06 Aventis Pharma S.A. Process for the preparation of combretastatins
US20040063502A1 (en) * 2002-09-24 2004-04-01 Intec, Inc. Power module
US20040224768A1 (en) * 2002-09-24 2004-11-11 Saied Hussaini Video game controller with integrated status indicators
CN1744892A (zh) 2003-02-04 2006-03-08 株式会社益力多本社 乳癌耐性蛋白(bcrp)抑制剂
AU2004218412A1 (en) * 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
GB2403949A (en) * 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Combretastatin derivatives
SG164378A1 (en) * 2005-02-17 2010-09-29 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
CN1301246C (zh) * 2005-04-20 2007-02-21 江苏省原子医学研究所 1－氰基－1－(3,5－二甲氧基苯基)－2－(4－r基苯基)乙烯及其制备方法
EP1746087A1 (de) 2005-07-21 2007-01-24 Universitaet Regensburg 3-Indolylmethylen-Derivate mit cytostatischer Wirkung
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN101139358B (zh) 2006-09-07 2011-10-12 浙江大德药业集团有限公司 乙氧基康普立停及其前药的制备和用途
US20090170841A1 (en) 2007-04-20 2009-07-02 Acucela Inc. Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders
US20090192098A1 (en) 2007-11-21 2009-07-30 Oxigene, Inc. Method for treating hematopoietic neoplasms
FR2928148B1 (fr) * 2008-02-28 2013-01-18 Sanofi Aventis Procede de preparation de combretastatine
FR2945210B1 (fr) 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
FR2953518B1 (fr) * 2009-12-03 2012-01-20 Sanofi Aventis Procede de preparation d'un derive de combretastatine
US20130131018A1 (en) 2010-06-04 2013-05-23 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
MX2012014732A (es) 2010-06-18 2013-01-22 Sanofi Sa Una combinacion antitumoral que comprende ombrabulina un derivado de taxano y un derivado de platino.
EP2481404A1 (en) 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2397135A1 (en) 2010-06-18 2011-12-21 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2407161A1 (en) 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
FR2968557A1 (fr) 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
CN110015962B (zh) 2011-01-28 2022-03-15 肯塔基大学研究基金会 茋类似物和治疗癌症的方法
CN102863388B (zh) 2011-07-05 2015-04-29 南京圣和药业股份有限公司 肿瘤靶向药物Combretastatin A4衍生物
WO2013084150A1 (en) * 2011-12-06 2013-06-13 Sanofi Novel crystal form of (2s)-2-amino-3-hydroxy-n-[2-methoxy-2-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide and method of preparation thereof
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN103012248B (zh) * 2013-01-11 2014-11-05 浙江大德药业集团有限公司 氨基康普立停衍生物的合成及其作为口服抗肿瘤药物的应用
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
US9458086B1 (en) 2013-07-03 2016-10-04 University Of South Florida (A Florida Non-Profit Corporation) Compositions and methods for adipocyte modulation
BR112016017993A2 (pt) 2014-02-03 2017-08-08 Quadriga Biosciences Inc Gama-aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos
US9394237B2 (en) * 2014-02-03 2016-07-19 Quadriga Biosciences, Inc. β-substituted β-amino acids and analogs as chemotherapeutic agents
US9487482B2 (en) * 2014-05-09 2016-11-08 Council Of Scientific And Industrial Research 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents
KR20180035894A (ko) 2015-08-03 2018-04-06 콰드리가 바이오사이언시스 인코포레이티드 화학치료제로서의 베타-치환된 베타-아미노산 및 유사체 및 이들의 용도
WO2017031157A1 (en) 2015-08-18 2017-02-23 Mateon Therapeutics, Inc. Use of vdas to enhance immunomodulating therapies against tumors
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CN112225673B (zh) * 2020-11-13 2022-08-02 义乌市华耀医药科技有限公司 氨基康普立停衍生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL250327A (ko) * 1959-04-08
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
EP0641301A1 (en) 1992-05-21 1995-03-08 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
JP3180127B2 (ja) * 1993-03-10 2001-06-25 森永乳業株式会社 スチルベン誘導体とスチルベン同族体誘導体及びそれらの用途
TW325458B (en) * 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer

Also Published As

Publication number Publication date
CA2171275A1 (en) 1996-09-08
EP0731085B1 (en) 1999-10-20
CN1143629A (zh) 1997-02-26
PT731085E (pt) 2000-04-28
CN1066713C (zh) 2001-06-06
CA2171275C (en) 2005-12-20
US5674906A (en) 1997-10-07
DK0731085T3 (da) 2000-04-17
DE69604714D1 (de) 1999-11-25
ATE185792T1 (de) 1999-11-15
GR3032311T3 (en) 2000-04-27
DE69604714T2 (de) 2000-06-15
KR100352048B1 (ko) 2003-05-12
TW334418B (en) 1998-06-21
ES2137628T3 (es) 1999-12-16
EP0731085A1 (en) 1996-09-11

Similar Documents

Publication Publication Date Title
KR960034164A (ko) 스틸벤 유도체 및 이를 함유하는 약제학적 조성물
KR950000728A (ko) 포스포네이트 뉴클레오티드 에스테르 유도체
BR0007500A (pt) Composto triazol, fármaco, e, uso do composto
PT1140993E (pt) Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
FI822543A0 (fi) Pyrrolidinderivat
KR960007592A (ko) 신규한 피롤로카바졸
KR900009606A (ko) 불소-함유 2-니트로 이미다졸 유도체 및 그를 함유하는 방사선 증감제
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
HUP9901212A2 (hu) N,N-dialkil-N-[2-(3-alkoxi-fenoxi)-etil]-amin-származékok, az ezeket tartalmazó gyógyszerkészítmények és helyi érzéstelenítőkként való alkalmazásuk
KR970706251A (ko) 항종양제 및 항바이러스제로서의 비스-(2-할로에틸)아미노페닐 치환된 디스타마이신 유도체(Bis-(2-haloethyl)aminophenyl substituted distamycin derivatives as antitumor and antiviral agents)
KR960041178A (ko) 신규의 퀴나졸린 화합물 및 활성 성분으로서 이를 함유하는 항종양제
AR044175A1 (es) Compuestos de cefemo
KR890001965A (ko) 스퍼구알린 관련 유도체
DK601683A (da) Dialkylaminoalkoxybenzylalkoholderivater
TR200504091T2 (tr) (7alfa,17alfa)-17-hidroksi-7-metil-19-nor-17-pregn-5(10)-en 20-in-3-on içeren yüksek saflıkta bileşim.
EA199901012A1 (ru) Фармацевтические композиции на основе тизоксанида и нитазоксанида
KR960029319A (ko) 4-아미노벤조일구아니딘 유도체
RU95104235A (ru) Агент для контроля плодовитости и содержащая его фармацевтическая композиция
BR0211656A (pt) Formulação farmacêutica em aerossol, composto ou um sal ou solvato deste, processo para a preparação de compostos, e, uso de um composto
KR910009718A (ko) 프라디미신 유도체
DE69827614D1 (de) Chinoxalindionen
KR920017660A (ko) 의약품
BR9807506A (pt) Derivados de amida e composições medicinais dos mesmos
KR970704463A (ko) 스트렙토그라민 유도체, 이의 제조 방법 및 이를 함유하는 약학 조성물(streptogramine derivatives, preparation of same and pharmaceutical compositions containing same)
KR940018351A (ko) 노나테트라에노산 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130801

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20140808

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20150730

Year of fee payment: 14

EXPY Expiration of term